Tan M, Lamendola C, Luong R, et al. - Researchers performed this phase 2, multiple‐ascending‐dose study to test the safety, effectiveness and pharmacokinetics of repeat dosing of two formulations of subcutaneous (SC) avexitide (exendin 9‐39) in individuals with post‐bariatric hypoglycaemia (PBH). This investigation was carried out at Stanford University. Nineteen women with PBH had a baseline oral glucose tolerance test, with metabolic and symptomatic assessments. Fourteen women were then sequentially assigned to obtain one of four ascending‐dose levels of twice‐daily lyophilized (Lyo) avexitide by SC injection for 3 days. Twice‐daily administration of SC avexitide in patients with PBH effectively elevated the glucose nadir and prevented severe hypoglycaemia that needed rescue intervention. Avexitide can constitute a viable PBH therapy.